Vivos Therapeutics, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD from Q1 2020 to Q4 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
-
Summary
-
Vivos Therapeutics, Inc. quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q1 2020 to Q4 2024.
- Vivos Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending December 31, 2024 was $3.7M, a 13.9% increase year-over-year.
- Vivos Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending December 31, 2024 was $15M, a 8.91% increase year-over-year.
- Vivos Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $15M, a 8.91% increase from 2023.
- Vivos Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $13.8M, a 13.9% decline from 2022.
- Vivos Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $16M, a 5.1% decline from 2021.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)